Related Experiment Video

Updated: May 12, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

New driver mutations in non-small-cell lung cancer

William Pao1, Nicolas Girard

  • 1Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232–6307, USA. william.pao@vanderbilt.edu

The Lancet. Oncology
|February 1, 2011
PubMed

Insights

This review focuses on molecular subsets in non-small-cell lung cancer, beyond EGFR and KRAS, that are relevant for targeted therapies. Understanding these genetic drivers could personalize lung cancer treatment for better outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer treatment traditionally relies on tumor histology.
  • Emerging understanding of tumor molecular composition drives targeted therapy development.
  • Identifying specific gene mutations is crucial for effective cancer cell targeting.

Purpose of the Study:

  • To review molecular subsets in non-small-cell lung cancer (NSCLC) with clinical relevance for targeted therapies.
  • To focus on driver mutations beyond EGFR and KRAS.
  • To highlight the potential of genetically tailored treatments.

Main Methods:

  • Literature review of current knowledge on molecular subsets in NSCLC.
  • Focus on driver mutations in specific genes: ALK, HER2 (ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET.
  • Exclusion of extensively reviewed EGFR and KRAS mutations.

Main Results:

  • Several molecular subsets defined by driver mutations (ALK, HER2, BRAF, PIK3CA, AKT1, MAP2K1, MET) are identified in NSCLC.
  • These subsets show potential clinical relevance for targeted therapeutic strategies.
  • The study emphasizes the importance of these genetic alterations in cancer progression.

Conclusions:

  • Personalized treatment based on tumor genetics represents a paradigm shift in lung cancer care.
  • Targeted therapies directed at specific molecular subsets may lead to substantial therapeutic improvements.
  • Further research into these genetic drivers is warranted to optimize patient outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Mutations01:39

Mutations

Overview
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...